Evidence map›Paper›PMID 38848719›Full record

ArticleCancer cell2024

Engineering focusing on cancer.

Kayvan R Keshari, Daniel A Heller, Rostislav Boltyanskiy, Hedvig Hricak, Thomas Magaldi, Michael Overholtzer

Abstract read
In one paragraph

Article in Cancer cell, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Near-Infrared Conjugated Macrocyclic BODIPYs for Photothermal Cancer Therapy.Angewandte Chemie (International ed. in English) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kayvan R KeshariMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Gerstner Sloan Kettering School for Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Center for Molecular Imaging and Bioengineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: rahimikk@mskcc.org.
Daniel A HellerMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Gerstner Sloan Kettering School for Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Center for Molecular Imaging and Bioengineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: hellerd@mskcc.org.
Rostislav BoltyanskiyCenter for Molecular Imaging and Bioengineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Hedvig HricakMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Gerstner Sloan Kettering School for Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Center for Molecular Imaging and Bioengineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Thomas MagaldiGerstner Sloan Kettering School for Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Michael OverholtzerCell Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Gerstner Sloan Kettering School for Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Center for Molecular Imaging and Bioengineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: overhom1@mskcc.org.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Regulated cell death and responses to starvation in cancerR35CA263846 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Michael H. Overholtzer · 2022 to 2026
$4.5M
Leveraging fructose transport to create a privileged substrate to selectively fuel T cellsR01CA248364 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Kayvan R Keshari · 2021 to 2026
$4.3M
Development of large-field-of-view hyperpolarized MRIR01CA237466 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CUNNINGHAM, CHARLES H., HRICAK, HEDVIG · 2020 to 2024
$3.4M
Visualizing oxidative stress using hyperpolarized magnetic resonanceR01CA252037 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI KESHARI, KAYVAN R · 2020 to 2024
$3.3M
P-selectin-Mediated Targeting of PI3K Nanomedicines to the Tumor MicroenvironmentR01CA215719 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI HELLER, DANIEL ALAN · 2018 to 2022
$3.1M
Tumor-Selective Delivery Approaches for MedulloblastomaR01NS116353 · NINDS · SLOAN-KETTERING INST CAN RESEARCH · PI HELLER, DANIEL ALAN, RAJU, PRAVEEN B. · 2020 to 2024
$3.1M
Interrogation of the oxidative-stress-induced leukemia program in vivo usingmetabolic imagingR01CA283578 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Kayvan R Keshari, Michael Kharas · 2023 to 2026
$3.0M
Inducing Neural Maturation in Medulloblastoma by Targeting EZH2R01NS122987 · NINDS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI RAJU, PRAVEEN B., SNUDERL, MATIJA · 2022 to 2025
$2.8M
Nanosensor Array Platform to Capture Whole Disease FingerprintsR01EB033651 · NIBIB · SLOAN-KETTERING INST CAN RESEARCH · PI Daniel Alan Heller · 2023 to 2026
$2.6M
Image-guided Trp-IDO/TDO-Kyn-AHR pathway inhibition, combined with immunotherapyR01CA249294 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI KESHARI, KAYVAN R, MERGHOUB, TAHA · 2021 to 2025
$2.6M
Nanotechnology as a therapeutic approach in arteriovenous fistula maturationR01DK129299 · NIDDK · UNIVERSITY OF UTAH · PI JAIMES, EDGAR A, SHIU, YAN-TING E. · 2021 to 2024
$1.7M
NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA215719NCI NIH HHS R01 CA237466NCI NIH HHS R01 CA248364NCI NIH HHS R01 CA249294NCI NIH HHS R01 CA252037NCI NIH HHS R01 CA283578NCI NIH HHS R35 CA263846NIBIB NIH HHS R01 EB033651NIDDK NIH HHS R01 DK114321NIDDK NIH HHS R01 DK129299NINDS NIH HHS R01 NS116353NINDS NIH HHS R01 NS122987
6 · The paper itself

Abstract

While cancer research and care have benefited from revolutionary advances in the ability to manipulate and study living systems, the field is limited by a lack of synergy to leverage the power of engineering approaches. Cancer engineering is an emerging subfield of biomedical engineering that unifies engineering and cancer biology to better understand, diagnose, and treat cancer. We highlight cancer engineering's unique challenges, the importance of creating dedicated centers and departments that enable translational collaboration, and educational approaches to arm a new generation of scientists with engineering expertise and a fundamental understanding of cancer biology to transform clinical cancer care.

Indexed as

NeoplasmsAnimalsBiomedical EngineeringHumans

Identifiers

PMID38848719
PMCPMC12282263

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.